Reports
Reports
The market for biotechnology is growing robustly due to a convergence of drivers reflecting scientific, technological advancements, and evolving healthcare requirements of the world. Among the key drivers for this growth is increased demand for biopharmaceuticals, which provide superior and more precise methods of managing chronic ailments and genetic diseases.
As the world continues to age, both - the prevalence of such health challenges and demands for new therapeutics are increasing, further diversifying the need for novel therapeutics. In addition, the growing discoveries from genomic research - including continually advancing CRISPR tools, next-sequencing tools - are facilitating the development of personalized medicine, providing avenues for treatment that are based on the patients' genetic composition.
In addition, higher public and private investment in research and development activities is driving biotechnology innovation with a very high-value pipeline of new products and therapies. Encouraged by this investment, supportive regulatory mechanisms enable biotechnological research and expedite the approval processes to allow faster access to market for new therapies.
The ongoing trend is the advent of personalized medicine, enabled by advances in genomics and biotechnology. Personalized medicine gives an individual customized care based on their genetics. Overall, this trend enhances the patient's experience and develops a more specialized healthcare system. Additionally, artificial intelligence’s and machine learning’s use for drug discovery and development activities is accelerating research, thereby bringing down time-to-market, and maximizing clinical trial efficiency.
The COVID-19 pandemic has also accelerated the adoption of biotechnological solutions, emphasizing the urgency for rapid vaccine development and biomanufacturing. Increased strategic partnerships and collaborations among biotech firms, pharma companies, and research organizations are also emerging to encourage knowledge sharing and pooling resources for stimulation of innovation. Taken collectively, all these trends suggest an active biotechnology sector that is addressing not only current health issues, but also preparing to innovate for future solutions to health care, agriculture, and environmental quality problems.
Biotechnology is an interdisciplinary science that employs biological systems, organisms, or derivatives to create products and technologies to enhance several dimensions of human life and the environment. Biotechnology, in essence, applies concepts of biology, chemistry, genetics, and engineering to control living organisms for utilitarian ends. The extent of the impact of biotechnology is extensive and paradigmatic, notably in medicine, agriculture, and ecology.
In medicine, biotechnology has revolutionized the development of drugs, vaccine development, and diagnostic technology. Biotechnology allows genetic material to be manipulated, which often occurs through genetic engineering and molecular biology. Through gene manipulation, manufacturers can produce biologics - drugs produced by using living organisms to directly attack the disease in a more specific way as compared to traditional drugs. New biotech technological advances such as monoclonal antibodies and gene therapy have improved the treatment of cancer and genetic diseases.
Biotechnology used in agriculture has rendered significant improvements in food production as well as sustainability efforts. GMOs are engineered to have best traits like being resistant to pests, drought tolerance, and increased nutrition. Farmers have been able to yield higher quantities while limiting the use of chemical pesticides and fertilizers, thereby fostering more sustainable agriculture. Biotechnology is also very important in the production of biodegradable products and biofuels, which lead to a sustainable agriculture environment.
Environmental biotechnology is generally concerned with utilizing biological processes to solve environmental problems. Examples include bioremediation, where contaminated soil and water is cleared using microorganisms and waste management techniques to convert organic waste into useful products. Biotechnology is also useful for preserving biodiversity by conserving endangered species through tissue culture and genetic banking.
| Attribute | Detail |
|---|---|
| Biotechnology Market Drivers |
|
The increasing demand for biopharmaceuticals portrays a critical growth factor to the biotechnology market while indicating a notable shift in the healthcare and medicine landscape. Biopharmaceuticals include many products derived from biological sources, namely proteins, nucleic acids, or living cells, and have become a significant alternative to chemical-based pharmaceuticals.
Among the drivers of biopharmaceuticals’ demand is the increasing prevalence of diseases like diabetes, cancer, and autoimmune diseases. Aging leads to these diseases, and hence the need for advanced treatment methods. Biopharmaceuticals provide targeted drugs, which can treat the fundamental cause of such diseases in a better way as compared to traditional drugs, with the result being better patient outcomes. For example, monoclonal antibodies have transformed the treatment of cancer by targeting tumor cells selectively and reducing damage to normal tissue while improving efficacy.
Furthermore, increase in administration of personalized medicine is driving the demand for biopharmaceuticals. Genomics and proteomics advancements make it possible to come up with more targeted therapy with reduced side effects. Personalization is critical in therapeutic markets such as oncology, where the selection of a patient's ideal treatment is based on genetic profiling of their cancer profile.
The biotechnology-oriented revolution of recombinant DNA technology and cell culture technologies has also contributed to the stimulation of growth of biopharmaceuticals. The technologies have enhanced the development process and manufacturing process to make the production of complex biological molecules at a large scale possible. Further, growing investment in research and development activities by pharmaceutical industries and biotech industries has produced a strong pipeline of new biopharmaceutical products.
Regulatory support and supportive reimbursement policy have also promoted the development of the biopharmaceutical industry. Regulatory bodies have implemented procedures for accelerated approval of biopharmaceuticals, especially for orphan disease indications.
In addition, as healthcare systems understand that biopharmaceuticals are cost-saving in the long term since they can potentially curtail hospitalization rates and enhance quality of life, there is also an increasing willingness to reimburse such treatments, thus accelerating their implementation.
Ongoing innovation in genomics and personalized medicine are key drivers of growth of the biotechnology industry, transforming disease diagnosis, treatment, and understanding in a revolutionary way. Genomics, or the analysis of the entire DNA content of an organism, has grown exponentially with advances in technologies like next-generation sequencing (NGS), which makes whole-genome sequencing affordable and viable. This has brought an ultradeep understanding of genetic variation and how that affects health, allowing the potential to leave behind one-size-fits-all therapy in favor of more tailored therapeutic intervention.
Personalized medicine uses these genomic data to customize medical treatment according to individuals' genetic constitution, lifestyle, and environment. The method is most important for multifactor etiology diseases such as cancer, whose genetic constitution differs widely from person to person. For instance, targeted drugs aim to suppress specifically the growth of cancer cells that have certain genetic mutations.
The increasing role of genomics in clinical practice is reshaping diagnostic approaches. Genomic testing advances will allow for earlier and often more precise diagnoses of diseases, including inherited diseases. Genetic testing, for example, can determine individuals at risk for certain diseases before symptoms develop, so that intervention can be planned and prevention strategies addressed. This will also save on future costs of healthcare by preventing disease progression.
The DNA sequencing segment of market is the biggest portion of the global biotechnology market. That is due to the growing technology advancements in sequencing technologies like next-generation sequencing (NGS) which reduce the cost and time needed for analyzing the genome, and provide a wide range of research and clinical applications. For example, the increasing demand for personalized medicine will require a complete genomic coverage to enable a precision approach to individualized treatment based on genetic differences.
As healthcare transitions to a model of precision medicine, DNA sequencing is poised to play a critical role in identifying genetic differences in relation to diseases.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest biotechnology market analysis, North America dominated in the market in 2024. The region consists of a strong ecosystem of top-performing biotech firms, research institutions, and universities that fuel innovation and collaboration. Having San Francisco and Boston as top biotech hubs, the region is favored with huge investment and skills, propelling research and development innovations.
Secondly, there is substantial private and public investment capitalizing on biotechnology development. Government initiatives such as grants offered by the National Institutes of Health (NIH) and encouraging policies provide a conducive environment for innovation. Furthermore, venture capital investments in biotech start-ups are record high, assisting in the development of new drugs and technologies.
In addition, the growing emphasis on personalized medicine and cutting-edge therapies in North America is consistent with the growing demand for biopharmaceuticals fueling market growth. The strong intellectual property system in the region also facilitates innovation through the protection of innovations by firms. Overall, these factors make North America the global leader in the world biotechnology market.
The leading biotech firms are wagering on new gene-editing technologies such as CRISPR to design therapy for genetic disease. Researchers are making efforts to move such therapies from the bench to the bedside, which has the potential to treat what was previously not treatable. Firms are also expanding their vaccine research and manufacturing capabilities. Initiatives include mRNA technology applications for various infectious diseases and rapid response platforms for future pandemics.
Abbott, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Novo Nordisk A/S, Merck KGaA, Johnson & Johnson Services, Inc., Amgen Inc., GSK plc, Sanofi, Thermo Fisher Scientific Inc., AbbVie Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Biogen Inc., and Moderna, Inc. are some of the leading players operating in the global biotechnology market.
Each of these players has been profiled in the biotechnology market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 1.8 Tn |
| Forecast Value in 2035 | US$ 5.4 Tn |
| CAGR | 10.3% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Tn |
| Biotechnology Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global biotechnology market was valued at US$ 1.8 Tn in 2024.
The global biotechnology industry is projected to reach more than US$ 5.4 Tn by the end of 2035.
Rising demand for biopharmaceuticals, ongoing advancements in genomics and personalized medicine and favorable government policies and regulatory incentives for biotechnology research and commercialization.
The CAGR is anticipated to be 10.3% from 2025 to 2035.
Abbott, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Novo Nordisk A/S, Merck KGaA, Johnson & Johnson Services, Inc., Amgen Inc., GSK plc, Sanofi, Thermo Fisher Scientific Inc., AbbVie Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Biogen Inc., and Moderna, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Biotechnology Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Biotechnology Market Analysis and Forecasts, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Tn)
5. Key Insights
5.1. Healthcare Expenditure across Key Regions / Countries
5.2. Technological Advancements
5.3. Regulatory Scenario across Key Regions / Countries
5.4. PORTER’s Five Forces Analysis
5.5. PESTEL Analysis
5.6. Value Chain Analysis
5.7. Key Purchase Metrics for End-users
5.8. Go-to-Market Strategy for New Market Entrants
5.9. Key Industry Events (Partnerships, Collaborations, Product approvals, Mergers & acquisitions)
5.10. Benchmarking of Key Technologies Offered by the Leading Competitors
6. Global Biotechnology Market Analysis and Forecasts, By Technology
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Technology, 2020 to 2035
6.3.1. Polymerase Chain Reaction (PCR) Technology
6.3.2. Tissue Engineering and Regeneration
6.3.3. Nanobiotechnology
6.3.4. Chromatography
6.3.5. DNA Sequencing
6.3.6. Cell-based Assays
6.3.7. Fermentation
6.3.8. Bioinformatics
6.3.9. Others
6.4. Market Attractiveness By Technology
7. Global Biotechnology Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2020 to 2035
7.3.1. Healthcare
7.3.2. Agriculture
7.3.3. Food & Beverages
7.3.4. Industrial Biotechnology
7.3.5. Environmental Biotechnology
7.3.6. Others
7.4. Market Attractiveness By Application
8. Global Biotechnology Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Region
9. North America Biotechnology Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Technology, 2020 to 2035
9.2.1. Polymerase Chain Reaction (PCR) Technology
9.2.2. Tissue Engineering and Regeneration
9.2.3. Nanobiotechnology
9.2.4. Chromatography
9.2.5. DNA Sequencing
9.2.6. Cell-based Assays
9.2.7. Fermentation
9.2.8. Bioinformatics
9.2.9. Others
9.3. Market Value Forecast By Application, 2020 to 2035
9.3.1. Healthcare
9.3.2. Agriculture
9.3.3. Food & Beverages
9.3.4. Industrial Biotechnology
9.3.5. Environmental Biotechnology
9.3.6. Others
9.4. Market Value Forecast By Country, 2020 to 2035
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Technology
9.5.2. By Application
9.5.3. By Country
10. Europe Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Technology, 2020 to 2035
10.2.1. Polymerase Chain Reaction (PCR) Technology
10.2.2. Tissue Engineering and Regeneration
10.2.3. Nanobiotechnology
10.2.4. Chromatography
10.2.5. DNA Sequencing
10.2.6. Cell-based Assays
10.2.7. Fermentation
10.2.8. Bioinformatics
10.2.9. Others
10.3. Market Value Forecast By Application, 2020 to 2035
10.3.1. Healthcare
10.3.2. Agriculture
10.3.3. Food & Beverages
10.3.4. Industrial Biotechnology
10.3.5. Environmental Biotechnology
10.3.6. Others
10.4. Market Value Forecast By Country / Sub-region, 2020 to 2035
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Switzerland
10.4.7. The Netherlands
10.4.8. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Technology
10.5.2. By Application
10.5.3. By Country / Sub-region
11. Asia Pacific Biotechnology Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Technology, 2020 to 2035
11.2.1. Polymerase Chain Reaction (PCR) Technology
11.2.2. Tissue Engineering and Regeneration
11.2.3. Nanobiotechnology
11.2.4. Chromatography
11.2.5. DNA Sequencing
11.2.6. Cell-based Assays
11.2.7. Fermentation
11.2.8. Bioinformatics
11.2.9. Others
11.3. Market Value Forecast By Application, 2020 to 2035
11.3.1. Healthcare
11.3.2. Agriculture
11.3.3. Food & Beverages
11.3.4. Industrial Biotechnology
11.3.5. Environmental Biotechnology
11.3.6. Others
11.4. Market Value Forecast By Country / Sub-region, 2020 to 2035
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. South Korea
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Technology
11.5.2. By Application
11.5.3. By Country / Sub-region
12. Latin America Biotechnology Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Technology, 2020 to 2035
12.2.1. Polymerase Chain Reaction (PCR) Technology
12.2.2. Tissue Engineering and Regeneration
12.2.3. Nanobiotechnology
12.2.4. Chromatography
12.2.5. DNA Sequencing
12.2.6. Cell-based Assays
12.2.7. Fermentation
12.2.8. Bioinformatics
12.2.9. Others
12.3. Market Value Forecast By Application, 2020 to 2035
12.3.1. Healthcare
12.3.2. Agriculture
12.3.3. Food & Beverages
12.3.4. Industrial Biotechnology
12.3.5. Environmental Biotechnology
12.3.6. Others
12.4. Market Value Forecast By Country / Sub-region, 2020 to 2035
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Technology
12.5.2. By Application
12.5.3. By Country / Sub-region
13. Middle East & Africa Biotechnology Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Technology, 2020 to 2035
13.2.1. Polymerase Chain Reaction (PCR) Technology
13.2.2. Tissue Engineering and Regeneration
13.2.3. Nanobiotechnology
13.2.4. Chromatography
13.2.5. DNA Sequencing
13.2.6. Cell-based Assays
13.2.7. Fermentation
13.2.8. Bioinformatics
13.2.9. Others
13.3. Market Value Forecast By Application, 2020 to 2035
13.3.1. Healthcare
13.3.2. Agriculture
13.3.3. Food & Beverages
13.3.4. Industrial Biotechnology
13.3.5. Environmental Biotechnology
13.3.6. Others
13.4. Market Value Forecast By Country / Sub-region, 2020 to 2035
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Technology
13.5.2. By Application
13.5.3. By Country / Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2024)
14.3. Company Profiles
14.3.1. Abbott
14.3.1.1. Company Overview
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. Business Strategies
14.3.1.5. Recent Developments
14.3.2. AstraZeneca
14.3.2.1. Company Overview
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. Business Strategies
14.3.2.5. Recent Developments
14.3.3. Pfizer Inc.
14.3.3.1. Company Overview
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. Business Strategies
14.3.3.5. Recent Developments
14.3.4. F. Hoffmann-La Roche AG
14.3.4.1. Company Overview
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. Business Strategies
14.3.4.5. Recent Developments
14.3.5. Novartis AG
14.3.5.1. Company Overview
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. Business Strategies
14.3.5.5. Recent Developments
14.3.6. Merck & Co., Inc.
14.3.6.1. Company Overview
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. Business Strategies
14.3.6.5. Recent Developments
14.3.7. Eli Lilly and Company
14.3.7.1. Company Overview
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. Business Strategies
14.3.7.5. Recent Developments
14.3.8. Novo Nordisk A/S
14.3.8.1. Company Overview
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. Business Strategies
14.3.8.5. Recent Developments
14.3.9. Merck KGaA
14.3.9.1. Company Overview
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. Business Strategies
14.3.9.5. Recent Developments
14.3.10. Johnson & Johnson Services, Inc.
14.3.10.1. Company Overview
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. Business Strategies
14.3.10.5. Recent Developments
14.3.11. Amgen Inc.
14.3.11.1. Company Overview
14.3.11.2. Financial Overview
14.3.11.3. Product Portfolio
14.3.11.4. Business Strategies
14.3.11.5. Recent Developments
14.3.12. GSK plc
14.3.12.1. Company Overview
14.3.12.2. Financial Overview
14.3.12.3. Product Portfolio
14.3.12.4. Business Strategies
14.3.12.5. Recent Developments
14.3.13. Sanofi
14.3.13.1. Company Overview
14.3.13.2. Financial Overview
14.3.13.3. Product Portfolio
14.3.13.4. Business Strategies
14.3.13.5. Recent Developments
14.3.14. Thermo Fisher Scientific Inc.
14.3.14.1. Company Overview
14.3.14.2. Financial Overview
14.3.14.3. Product Portfolio
14.3.14.4. Business Strategies
14.3.14.5. Recent Developments
14.3.15. AbbVie Inc.
14.3.15.1. Company Overview
14.3.15.2. Financial Overview
14.3.15.3. Product Portfolio
14.3.15.4. Business Strategies
14.3.15.5. Recent Developments
14.3.16. Bristol-Myers Squibb Company
14.3.16.1. Company Overview
14.3.16.2. Financial Overview
14.3.16.3. Product Portfolio
14.3.16.4. Business Strategies
14.3.16.5. Recent Developments
14.3.17. Teva Pharmaceutical Industries Ltd.
14.3.17.1. Company Overview
14.3.17.2. Financial Overview
14.3.17.3. Product Portfolio
14.3.17.4. Business Strategies
14.3.17.5. Recent Developments
14.3.18. Gilead Sciences, Inc.
14.3.18.1. Company Overview
14.3.18.2. Financial Overview
14.3.18.3. Product Portfolio
14.3.18.4. Business Strategies
14.3.18.5. Recent Developments
14.3.19. Biogen Inc.
14.3.19.1. Company Overview
14.3.19.2. Financial Overview
14.3.19.3. Product Portfolio
14.3.19.4. Business Strategies
14.3.19.5. Recent Developments
14.3.20. Moderna, Inc.
14.3.20.1. Company Overview
14.3.20.2. Financial Overview
14.3.20.3. Product Portfolio
14.3.20.4. Business Strategies
14.3.20.5. Recent Developments
List of Tables
Table 01: Global Biotechnology Market Value (US$ Tn) Forecast, By Technology, 2020 to 2035
Table 02: Global Biotechnology Market Value (US$ Tn) Forecast, By Application, 2020 to 2035
Table 03: Global Biotechnology Market Value (US$ Tn) Forecast, By Region, 2020 to 2035
Table 04: North America - Biotechnology Market Value (US$ Tn) Forecast, by Country, 2020 to 2035
Table 05: North America - Biotechnology Market Value (US$ Tn) Forecast, By Technology, 2020 to 2035
Table 06: North America - Biotechnology Market Value (US$ Tn) Forecast, By Application, 2020 to 2035
Table 07: Europe - Biotechnology Market Value (US$ Tn) Forecast, by Country / Sub-region, 2020 to 2035
Table 08: Europe - Biotechnology Market Value (US$ Tn) Forecast, By Technology, 2020 to 2035
Table 09: Europe - Biotechnology Market Value (US$ Tn) Forecast, By Application, 2020 to 2035
Table 10: Asia Pacific - Biotechnology Market Value (US$ Tn) Forecast, by Country / Sub-region, 2020 to 2035
Table 11: Asia Pacific - Biotechnology Market Value (US$ Tn) Forecast, By Technology, 2020 to 2035
Table 12: Asia Pacific - Biotechnology Market Value (US$ Tn) Forecast, By Application, 2020 to 2035
Table 13: Latin America - Biotechnology Market Value (US$ Tn) Forecast, by Country / Sub-region, 2020 to 2035
Table 14: Asia Pacific - Biotechnology Market Value (US$ Tn) Forecast, By Technology, 2020 to 2035
Table 15: Latin America - Biotechnology Market Value (US$ Tn) Forecast, By Application, 2020 to 2035
Table 16: Middle East & Africa - Biotechnology Market Value (US$ Tn) Forecast, by Country / Sub-region, 2020 to 2035
Table 17: Middle East & Africa - Biotechnology Market Value (US$ Tn) Forecast, By Technology, 2020 to 2035
Table 18: Middle East & Africa - Biotechnology Market Value (US$ Tn) Forecast, By Application, 2020 to 2035
List of Figures
Figure 01: Global Biotechnology Market Value Share Analysis, By Technology, 2024 and 2035
Figure 02: Global Biotechnology Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 03: Global Biotechnology Market Revenue (US$ Tn), by Polymerase Chain Reaction (PCR) Technology, 2020 to 2035
Figure 04: Global Biotechnology Market Revenue (US$ Tn), by Tissue Engineering and Regeneration, 2020 to 2035
Figure 05: Global Biotechnology Market Revenue (US$ Tn), by Nanobiotechnology, 2020 to 2035
Figure 06: Global Biotechnology Market Revenue (US$ Tn), by Chromatography, 2020 to 2035
Figure 07: Global Biotechnology Market Revenue (US$ Tn), by DNA Sequencing, 2020 to 2035
Figure 08: Global Biotechnology Market Revenue (US$ Tn), by Cell-based Assays, 2020 to 2035
Figure 09: Global Biotechnology Market Revenue (US$ Tn), by Fermentation, 2020 to 2035
Figure 10: Global Biotechnology Market Revenue (US$ Tn), by Bioinformatics, 2020 to 2035
Figure 11: Global Biotechnology Market Revenue (US$ Tn), by Others, 2020 to 2035
Figure 12: Global Biotechnology Market Value Share Analysis, By Application, 2024 and 2035
Figure 13: Global Biotechnology Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 14: Global Biotechnology Market Revenue (US$ Tn), by Healthcare, 2020 to 2035
Figure 15: Global Biotechnology Market Revenue (US$ Tn), by Agriculture, 2020 to 2035
Figure 16: Global Biotechnology Market Revenue (US$ Tn), by Food & Beverages, 2020 to 2035
Figure 17: Global Biotechnology Market Revenue (US$ Tn), by Industrial Biotechnology, 2020 to 2035
Figure 18: Global Biotechnology Market Revenue (US$ Tn), by Environmental Biotechnology, 2020 to 2035
Figure 19: Global Biotechnology Market Revenue (US$ Tn), by Others, 2020 to 2035
Figure 20: Global Biotechnology Market Value Share Analysis, By Region, 2024 and 2035
Figure 21: Global Biotechnology Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 22: North America - Biotechnology Market Value (US$ Tn) Forecast, 2020 to 2035
Figure 23: North America - Biotechnology Market Value Share Analysis, by Country, 2024 and 2035
Figure 24: North America - Biotechnology Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 25: North America - Biotechnology Market Value Share Analysis, By Technology, 2024 and 2035
Figure 26: North America - Biotechnology Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 27: North America - Biotechnology Market Value Share Analysis, By Application, 2024 and 2035
Figure 28: North America - Biotechnology Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 29: Europe - Biotechnology Market Value (US$ Tn) Forecast, 2020 to 2035
Figure 30: Europe - Biotechnology Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 31: Europe - Biotechnology Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 32: Europe - Biotechnology Market Value Share Analysis, By Technology, 2024 and 2035
Figure 33: Europe - Biotechnology Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 34: Europe - Biotechnology Market Value Share Analysis, By Application, 2024 and 2035
Figure 35: Europe - Biotechnology Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 36: Asia Pacific - Biotechnology Market Value (US$ Tn) Forecast, 2020 to 2035
Figure 37: Asia Pacific - Biotechnology Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 38: Asia Pacific - Biotechnology Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 39: Asia Pacific - Biotechnology Market Value Share Analysis, By Technology, 2024 and 2035
Figure 40: Asia Pacific - Biotechnology Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 41: Asia Pacific - Biotechnology Market Value Share Analysis, By Application, 2024 and 2035
Figure 42: Asia Pacific - Biotechnology Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 43: Latin America - Biotechnology Market Value (US$ Tn) Forecast, 2020 to 2035
Figure 44: Latin America - Biotechnology Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 45: Latin America - Biotechnology Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 46: Latin America - Biotechnology Market Value Share Analysis, By Technology, 2024 and 2035
Figure 47: Latin America - Biotechnology Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 48: Latin America - Biotechnology Market Value Share Analysis, By Application, 2024 and 2035
Figure 49: Latin America - Biotechnology Market Attractiveness Analysis, By Application, 2025 to 2035
Figure 50: Middle East & Africa - Biotechnology Market Value (US$ Tn) Forecast, 2020 to 2035
Figure 51: Middle East & Africa - Biotechnology Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 52: Middle East & Africa - Biotechnology Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 53: Middle East & Africa - Biotechnology Market Value Share Analysis, By Technology, 2024 and 2035
Figure 54: Middle East & Africa - Biotechnology Market Attractiveness Analysis, By Technology, 2025 to 2035
Figure 55: Middle East & Africa - Biotechnology Market Value Share Analysis, By Application, 2024 and 2035
Figure 56: Middle East & Africa - Biotechnology Market Attractiveness Analysis, By Application, 2025 to 2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Biotechnology Market